8hon MSN
In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. They discuss: How ...
The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...
4don MSN
We recently published a list of 10 Stocks With At Least $20 Million In Insider Spending Recently. In this article, we are ...
MET-097i achieved up to 11.3% mean placebo-adjusted weight loss at 12 weeks and exhibited a 380-hour (nearly 16-day) half-life and good tolerability. Metsera said the drug's profile is at least as ...
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...
Interesting Engineering on MSN3d
AI finds natural peptide that matches Ozempic’s weight loss power without side effectsStanford researchers have discovered BRP, a naturally occurring peptide that suppresses appetite and promotes weight loss, ...
CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback